<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034356</url>
  </required_header>
  <id_info>
    <org_study_id>MHBB-006-16S</org_study_id>
    <secondary_id>I01CX001414</secondary_id>
    <nct_id>NCT03034356</nct_id>
  </id_info>
  <brief_title>Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia</brief_title>
  <official_title>Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and
      cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure
      drug, also called an anticonvulsant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive symptoms are not currently well-managed in Veterans with schizophrenia, leading to
      substantially diminished quality of life. Improved treatment strategies clearly are needed.
      Recent studies suggest taht an overactive hippocampus is associated with cognitive deficits
      in the illness. Based on findings that the anti-epileptic drug levetiracetam (LEV) reduces
      hippocampal activity and improves cognition in other clinical populations while being safe
      and well-tolerated, this study will examine the effects of the drug on hippocampal activity
      and cognition in Veterans with schizophrenia. In this crossover design, participants will
      take LEV for 4 weeks and placebo pills for 4 weeks, but will not know the order in which they
      are taking them.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cognitive function as measured by the Repeatable Battery for the Assessment of Neurological Status (RBANS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting-state neuronal response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Neuronal response (measured via functional magnetic resonance imaging, fMRI) in the hippocampus during rest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Anticonvulsant drug</description>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Levetiracetam, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  Good general health

          -  Normal vital signs (blood pressure, pulse, respiration)

        Exclusion Criteria:

          -  Substance abuse

          -  Significant neurological disorders

          -  Significant head trauma/injury

          -  Pregnancy

          -  MRI-specific exclusion criteria, e.g.,:

               -  claustrophobia

               -  weight&gt;400 lbs

               -  metal in the body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason R. Tregellas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Eastern Colorado Health Care System, Denver, CO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason R Tregellas, PhD</last_name>
    <phone>(303) 315-1086</phone>
    <email>Jason.Tregellas@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason R Tregellas, PhD</last_name>
      <phone>303-315-1086</phone>
      <email>Jason.Tregellas@va.gov</email>
    </contact>
    <investigator>
      <last_name>Jason R. Tregellas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified, anonymized dataset will be created and shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

